SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

SGLT2 inhibitors show significant benefits in older adults with cardiovascular disease, with consistent benefits across subgroups based on diabetes status or age, a meta-analysis shows.

SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases in those with diabetes compared with sulfonylureas.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

People often call high blood pressure, or hypertension, the silent killer because it doesn't usually show any signs until it's too late. But if you don't get it treated it can slowly hurt the heart, ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. It is a great challenge to pay sustained ...

Series A financing will advance the company’s lead candidate for heart failure with reduced ejection fraction (HFrEF) through completion of early clinical development and GMP manufacturing scale-up ...